261 0 Kommentare Medgenics Announces Pricing of Public Offering of Common Stock

PHILADELPHIA, PA--(Marketwired - Jun 21, 2016) - Medgenics, Inc. (NYSE MKT: MDGN) today announced the pricing of 3,640,000 shares of its common stock in a previously announced underwritten public offering at a price to the public of $5.50 per share. In connection with the offering, Medgenics has also granted the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered to the public. Gross proceeds to Medgenics from the sale of shares are expected to be approximately $20 million, excluding any exercise of the underwriters' option to purchase up to an additional 546,000 shares of common stock. If the underwriters' option is exercised in full, gross proceeds will be approximately $23 million. The offering is expected to close on or about June 24, 2016 subject to customary closing conditions.

Jefferies LLC is acting as sole book-running manager for the proposed offering. JMP Securities LLC and Needham & Company, LLC are acting as co-managers.

All of the shares to be sold in the proposed offering are being sold by Medgenics, with net proceeds to be used for (i) product development activities, including the development of companion diagnostics for existing programs, (ii) patent maintenance fees and intellectual property support, (iii) licensing and research collaborations and (iv) general corporate purposes and working capital, which may include the acquisitions or licensing of complementary technologies, products or businesses.

A shelf registration statement relating to the shares of common stock described above has been previously filed with and declared effective by the U.S. Securities and Exchange Commission (SEC). This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

This offering is being made by means of a prospectus supplement and related prospectus. A preliminary prospectus supplement relating to the offering will be filed with the SEC and will be available on its website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus may be obtained from Jefferies LLC by mail at Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 547-6340, or by e-mail at Prospectus_Department@Jefferies.com.